{
    "clinical_study": {
        "@rank": "95860", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "enteric coated capsule"
            }, 
            {
                "arm_group_label": "MG 500mg", 
                "arm_group_type": "Experimental", 
                "description": "Metadoxine + garlic oil"
            }, 
            {
                "arm_group_label": "MG 1000mg", 
                "arm_group_type": "Experimental", 
                "description": "Metadoxine + garlic oil"
            }, 
            {
                "arm_group_label": "Metadoxine 500mg", 
                "arm_group_type": "Sham Comparator", 
                "description": "enteric coated capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the\n      Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease\n      and Alcoholic Hepatitis."
        }, 
        "brief_title": "Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis", 
        "condition": [
            "Alcoholic Fatty Liver Disease", 
            "Alcoholic Hepatitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Fatty Liver, Alcoholic", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Alcoholic", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022Patients over 18, under 70 years of age\n\n               -  The chronic alcohol intake patients\n\n                    -  Current the heavy drinker over 3month, Day the average alcohol consumption\n                       Male>=60g, Female>=40mg y-GTP increase Male>=75, Female>=35\n\n               -  Over 1.5 ratio of AST to ALT\n\n               -  Patients who have chronoc alcohol disease\n\n        Exclusion Criteria:\n\n          -  Patients who have liver disease with the cause different with the alcohol except\n\n          -  Patients who have pyridoxine allergy or history\n\n          -  Patients who are judged by investigator that participation of the study is difficult\n             due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor,\n             serious metabolic disease, severe renal disease, severe pulmonary disease, severe\n             cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease\n             and etc\n\n          -  Patients taking other investigational product within 90 days prior to the\n             participation in the study.\n\n          -  Patients who has been taken any medications that could affect the treatment :\n             hypoglycemic agents, colchicine, penicillamine, corticosteroids, ursodeoxycholic\n             acid, pentoxifylline, lont-term use of NSAIDs, statins, neuroleptics, anti convulsive\n             medications, high-dose acetaminophen(>=2.5g/day)\n\n          -  Patients who have received treatment that may affect liver function within 1 month\n             prior to the participation in the study\n\n          -  Patient who considered ineligible for participation in the study as Investigator's\n             judgment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019056", 
            "org_study_id": "MG"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo /bid P.O", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MG 500mg", 
                "intervention_name": "MG-1", 
                "intervention_type": "Drug", 
                "other_name": "MG500mg,Placebo /bid P.O"
            }, 
            {
                "arm_group_label": "MG 1000mg", 
                "intervention_name": "MG-2 : MG1000mg, Placebo  /bid P.O", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Metadoxine 500mg", 
                "intervention_name": "metadoxine", 
                "intervention_type": "Drug", 
                "other_name": "placebo, metadoxine 500mg/ bid P.O"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metadoxine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "contact": {
                "email": "circle0@hmc.hanyang.ac.kr", 
                "last_name": "Misoon Park", 
                "phone": "82-31-554-3115"
            }, 
            "facility": {
                "address": {
                    "city": "Guri city", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "471-701"
                }, 
                "name": "Hanyang university Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis", 
        "overall_contact": {
            "email": "isuclala@gmail.com", 
            "last_name": "SooHyun Lee", 
            "phone": "82-31-739-3344"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate the liver function to assess improvement of the MG on change in AST lab value assessed from baseline to  12 weeks in patients with Alcoholic fatty liver disease", 
                "measure": "Change from Baseline in AST at 14weeks", 
                "safety_issue": "No", 
                "time_frame": "14Weeks"
            }, 
            {
                "description": "Adverse Event: Physical examine, Lab test, Vital sign, ECG, symptom, start day and time, end day and time, severity, progress, outcome, relation with investigational product.", 
                "measure": "Number of Participants with Adverse Events (Safety)", 
                "safety_issue": "No", 
                "time_frame": "14weeks"
            }, 
            {
                "description": "To evaluate ALT normalization assessed by comparing the percentage.", 
                "measure": "To evaluate ALT normalization", 
                "safety_issue": "No", 
                "time_frame": "14weeks"
            }, 
            {
                "description": "To evaluate AST normalization assessed by comparing the percentage.", 
                "measure": "To evaluate AST normalization", 
                "safety_issue": "No", 
                "time_frame": "14weeks"
            }, 
            {
                "description": "To evaluate the efficacy of the MG on change in AST, ALT, total lab billirubin lab value assessed from baseline to 4, 8, 12 weeks in patients with Alcoholic fatty liver disease", 
                "measure": "change in AST, ALT, total lab billirubin lab value", 
                "safety_issue": "No", 
                "time_frame": "14weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019056"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "PharmaKing", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaKing", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}